Last reviewed · How we verify
Corlopam (FENOLDOPAM)
Corlopam (FENOLDOPAM) is a small molecule dopaminergic agonist that targets the D(1A) dopamine receptor. It was originally developed by Hospira and is currently owned by the same company. Corlopam is FDA-approved for the treatment of hypertensive urgency and malignant essential hypertension. The drug is off-patent, with multiple generic manufacturers available. Key safety considerations include its short half-life and low bioavailability.
At a glance
| Generic name | FENOLDOPAM |
|---|---|
| Sponsor | Pfizer |
| Drug class | Dopaminergic Agonist |
| Target | D(1A) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Hypertensive urgency
- Malignant essential hypertension
Common side effects
Key clinical trials
- Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants (PHASE2,PHASE3)
- The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery (NA)
- Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery (PHASE3)
- Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury (PHASE4)
- Vasodilators and Anti-Oxidant Therapy in Early ATN (PHASE2,PHASE3)
- Fenoldopam and Acute Renal Failure (PHASE3)
- An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery (PHASE2)
- Effect of Gene Variants on Dopamine Receptor Natriuretic Responses (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corlopam CI brief — competitive landscape report
- Corlopam updates RSS · CI watch RSS
- Pfizer portfolio CI